Wealthfront Advisers LLC Buys Shares of 9,249 IQVIA Holdings Inc. $IQV

Posted by Stanley Muller on Aug 21st, 2026

Wealthfront Advisers LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 9,249 shares of the medical research company’s stock, valued at approximately $1,787,000.

Other institutional investors also recently bought and sold shares of the company. Financial Freedom LLC purchased a new position in IQVIA in the first quarter valued at $25,000. Ascentis Independent Advisors acquired a new stake in IQVIA in the 1st quarter valued at about $25,000. International Assets Investment Management LLC purchased a new position in shares of IQVIA in the 4th quarter valued at about $27,000. Gilpin Wealth Management LLC acquired a new position in shares of IQVIA during the fourth quarter worth about $27,000. Finally, CrossGen Wealth LLC acquired a new stake in IQVIA in the fourth quarter valued at approximately $28,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

NYSE:IQV opened at $256.66 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The firm has a market cap of $42.25 billion, a price-to-earnings ratio of 31.84, a price-to-earnings-growth ratio of 2.12 and a beta of 1.18. The firm’s fifty day moving average price is $211.74 and its 200 day moving average price is $187.01. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $260.30.

IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business’s revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the firm posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its Board of Directors has approved a share buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Insider Activity

In related news, insider W Richard Staub sold 5,500 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the sale, the insider owned 13,312 shares in the company, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 12,913 shares of company stock valued at $3,098,793 over the last quarter. 1.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have commented on IQV shares. JPMorgan Chase & Co. boosted their price target on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Mizuho raised their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research note on Thursday, July 9th. TD Cowen raised their price target on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Finally, HSBC reaffirmed a “buy” rating and set a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

Check Out Our Latest Research Report on IQVIA

IQVIA Company Profile

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.